Anticoagulation for Pulmonary Embolism in Pregnancy

Introduction to Anticoagulation Therapy

The European Society of Cardiology recommends immediately initiating therapeutic-dose low molecular weight heparin (LMWH) at weight-based dosing for confirmed or highly suspected pulmonary embolism (PE) in pregnancy, regardless of miscarriage risk, as this is the only safe and effective anticoagulant option during pregnancy 1, 2, 3

For hemodynamically unstable (high-risk) PE, the American College of Cardiology suggests initiating intravenous unfractionated heparin (UFH) with weight-adjusted bolus first, then transitioning to LMWH once stabilized 1, 3
The European Society of Cardiology states that NOACs (including apixaban, rivaroxaban, dabigatran) are absolutely contraindicated in pregnancy and must be discontinued if the patient was taking them 1, 3

The American College of Chest Physicians recommends basing dosing on early pregnancy weight, not current weight 3
Anti-Xa monitoring is generally not required for routine cases but may be considered at extremes of body weight or with renal disease, according to the European Heart Journal 4

The presence of threatened or potential miscarriage does NOT contraindicate therapeutic anticoagulation for PE, as PE poses immediate life-threatening risk to the mother that supersedes bleeding concerns, as stated by the European Society of Cardiology 2
Enoxaparin does not cross the placenta and carries minimal fetal risk even in early pregnancy, according to the European Heart Journal 4

The American College of Cardiology recommends continuing therapeutic LMWH throughout entire pregnancy without switching to oral agents 2, 3
Warfarin is teratogenic in first trimester and causes fetal/neonatal hemorrhage in third trimester—never use during pregnancy, as stated by the European Heart Journal 4

The European Society of Cardiology suggests discontinuing LMWH at onset of regular uterine contractions or 24 hours before planned delivery 2, 3
Do not place epidural/spinal needle within 24 hours of last LMWH dose to avoid spinal hematoma, according to the American College of Cardiology 2, 3

Resume LMWH 4-12 hours after delivery (depending on bleeding risk and epidural catheter removal timing), as recommended by the European Society of Cardiology 2, 4
Transition to warfarin postpartum if desired; warfarin is safe during breastfeeding, according to the European Heart Journal 2, 4, 3
Minimum total treatment duration: 3 months, with at least 6 weeks postpartum, as stated by the American College of Cardiology 2, 4, 3

Underdosing LMWH due to bleeding concerns from threatened miscarriage—this increases maternal mortality risk from PE, according to the European Society of Cardiology 3
Placing epidural within 24 hours of LMWH administration, as warned by the American College of Cardiology 2, 3

Life-threatening PE with hemodynamic instability: Thrombolysis may be necessary despite pregnancy, with reported 94% maternal survival but 18% major bleeding during pregnancy and 58% bleeding postpartum, according to the European Heart Journal 2
Thrombolysis should be avoided peripartum except for truly life-threatening situations, as stated by the European Society of Cardiology 2, 4
Fetal death occurs in 12% of cases following maternal thrombolysis, according to the European Heart Journal 2

Mandatory team involvement includes obstetrics, hematology/thrombosis service, anesthesiology, and maternal-fetal medicine for coordinated care planning, particularly around delivery timing and epidural management, as recommended by the European Society of Cardiology 2, 3